Furthermore, in ER negative, Her-2 positive tumours, no response was observed to trastuzumab in patients with STAT3 activation [38] and that JAK2 drives a JAK1/STAT3-independent signaling program in triple negative breast cancer [39], demonstrated that there are different activators and targets for STAT3 in different subgroups of breast cancer. Here, JAK2 is linked to neoplasm.